BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 9951979)

  • 1. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
    Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
    Usonis V; Bakasenas V; Chitour K; Clemens R
    Infection; 1998; 26(4):222-6. PubMed ID: 9717679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
    Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)].
    Senterre J
    Rev Med Liege; 1999 Feb; 54(2):122-4. PubMed ID: 10221066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
    Klinge J; Lugauer S; Korn K; Heininger U; Stehr K
    Vaccine; 2000 Jul; 18(27):3134-40. PubMed ID: 10856793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.
    Gothefors L; Bergström E; Backman M
    Scand J Infect Dis; 2001; 33(7):545-9. PubMed ID: 11515768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: V. Usonis et al.: Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children (Infection 26 [1998] 222-226).
    Nalin D
    Infection; 1999; 27(2):134-5. PubMed ID: 10219647
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
    Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group.
    Reuman PD; Sawyer MH; Kuter BJ; Matthews H
    Pediatr Infect Dis J; 1997 Jul; 16(7):662-7. PubMed ID: 9239770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population.
    Edees S; Pullan CR; Hull D
    Public Health; 1991 Mar; 105(2):91-7. PubMed ID: 2068243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura.
    Pool V; Chen R; Rhodes P
    Pediatr Infect Dis J; 1997 Apr; 16(4):423-4. PubMed ID: 9109153
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of immunogenicity of simultaneous and nonsimultaneous vaccination with MMR and JE vaccine among 15-month-old children.
    Tseng CY; Hwang KP; Lin KH; Chen HY; Lu CC; Chiang CH
    Acta Paediatr Taiwan; 1999; 40(3):161-5. PubMed ID: 10910607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.